Mining publicly available single-cell RNA-sequencing (scRNA-seq) data in NSCLC reveals a wide distribution of NFE2L2 and G6PD (a key downstream effector of NRF2) 45, 47 expression across cancer cells, as well as diverse immune cell types, particularly within the myeloid lineage (Figure 4). Here, NFE2L2 is linked to non-small cell lung carcinoma.